ALK and non-small cell lung carcinoma: ALK inhibitors like lorlatinib, a third-generation TKI with effective central nervous system (CNS) penetration, have shown substantial efficacy in managing ALK-positive NSCLC, especially in cases with brain metastases (BMs) (Tao et al., 2022).